8th Aug. 2022, the 2nd China International Vaccine Innovation Summit (HVIS) took place in Beijing. The conference invited many professional specialists and scholars in BioMed, industry leaders, commercial dark horses, and senior media experts to participate. They discussed some entrepreneurial cases of BioMed and focused on how to define the business model of biotech by science, especially in company management, the direction of development, and investment potential. 

One sparkle in this convention was the "Future Star" award for participating BioMed companies. Abbisko Therapeutics was honored to receive the "Future Star" award from many companies. The standard of "Future Star" has six dimensions: technology, operation management, profit model, development, investment capital, and customer value. And many authoritative BioMed representatives to be the judges.

Abbisko Therapeutics deserves this award because the industry recognized the technology research and development, operation management, and market foresight of Abbisko. In the future, Abbisko Therapeutics will still stick to science and innovation and provide the best oncology medicines for patients in China and around the world.